Insulin-like growth factor 1 enhances renal function in a patient with chronic renal failure on peritoneal dialysis

• Published in: American journal of kidney diseases Vol. 35; no. 1; pp. 150 - 153
• Main Authors: Vijayan, Anitha, Franklin, Samuel C., Delmez, James A., Miller, Steven B.
• Format: Journal Article
• Language: English
• Published: Orlando, FL Elsevier Inc 2000; Elsevier
• Subjects: Aged; Biological and medical sciences; end-stage renal disease (ESRD); Female; Humans; Injections, Subcutaneous; insulin clearance; Insulin-like growth factor 1 (IGF1); Insulin-Like Growth Factor I - administration & dosage; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - genetics; Kidney Failure, Chronic - therapy; Kidney Function Tests; Medical sciences; peritoneal dialysis (PD); Peritoneal Dialysis, Continuous Ambulatory; Pharmacology. Drug treatments; Polycystic Kidney, Autosomal Dominant - genetics; Treatment Outcome; Uremia - blood; Uremia - genetics; Uremia - therapy; Urinary system; peritoneal dialysis (PD); insulin clearance; Insulin-like growth factor 1 (IGF1); end-stage renal disease (ESRD); Human; Kidney disease; Urinary system disease; Renal function; Polycystic kidney; Treatment efficiency; Terminal stage; Insulin like growth factor 1; Peritoneal dialysis; Genetic disease; Case study; Extrarenal dialysis; Chemotherapy; Chronic; Treatment; Polypeptide; Cyst; Renal failure; Adult; Benign neoplasm; Elderly; Growth factor
• ISSN: 0272-6386; 1523-6838
• DOI: 10.1016/S0272-6386(00)70322-2

Insulin-like growth factor 1 (IGF1) has been shown to improve renal function in healthy subjects, as well as those with chronic renal failure. To our knowledge, IGF1 has not been shown to be efficacious in patients who were already undergoing dialysis. We present the case of a 70-year-old woman with end-stage renal disease (ESRD) and overt uremic symptoms treated with IGF1 after peritoneal dialysis was discontinued because of complications. There was a significant improvement in her inulin clearance during the course of treatment. The patient remained well and did not require dialytic support for 19 weeks. Although further data are necessary, we believe this case shows that IGF1 may be a short-term alternative to dialysis in patients with ESRD.